Products - Liver cancers | Topic

Showing 12 products

Date | Sort by Title

Status: Awaiting developmentRemove ‘Status: Awaiting development’ filter

Selective internal radiation therapy for unresectable colorectal metastases in the liver
Status:
Awaiting development
Programme:
Interventional procedures guidance
Expected publication date:
29 November 2023
Nivolumab for adjuvant treatment of high-risk hepatocellular carcinoma after liver resection or ablation [ID3858]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
24 April 2024
Lenvatinib with pembrolizumab for untreated advanced or unresectable hepatocellular carcinoma [ID3930]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Cabozantinib with atezolizumab for untreated advanced hepatocellular carcinoma ID3940
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Pembrolizumab for adjuvant treatment of hepatocellular carcinoma [ID3994]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Durvalumab with bevacizumab and transarterial chemoembolisation for treating locally advanced hepatocellular carcinoma [ID3944]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Durvalumab with gemcitabine and cisplatin for untreated advanced biliary tract cancer [ID4031]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Lenvatinib with pembrolizumab and transarterial chemoembolization for untreated localised hepatocellular carcinoma TS ID 10503
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Durvalumab with transarterial chemoembolisation for treating incurable locally advanced hepatocellular carcinoma TS ID 10757
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Tislelizumab for untreated unresectable hepatocellular carcinoma TS ID 10683
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Atezolizumab with bevacizumab for adjuvant treatment of resected or ablated hepatocellular carcinoma at high risk of recurrence TS ID 10650
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Durvalumab (Imfinzi) +/- bevacizumab (Avastin) for hepatocellular carcinoma TS ID 10736
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC

Liver cancers Products

Filter

Product type

Guidance programme

Status
1 selected

New and updated

Showing 12 products

Selective internal radiation therapy for unresectable colorectal metastases in the liver

Nivolumab for adjuvant treatment of high-risk hepatocellular carcinoma after liver resection or ablation [ID3858]

Lenvatinib with pembrolizumab for untreated advanced or unresectable hepatocellular carcinoma [ID3930]

Cabozantinib with atezolizumab for untreated advanced hepatocellular carcinoma ID3940

Pembrolizumab for adjuvant treatment of hepatocellular carcinoma [ID3994]

Durvalumab with bevacizumab and transarterial chemoembolisation for treating locally advanced hepatocellular carcinoma [ID3944]

Durvalumab with gemcitabine and cisplatin for untreated advanced biliary tract cancer [ID4031]

Lenvatinib with pembrolizumab and transarterial chemoembolization for untreated localised hepatocellular carcinoma TS ID 10503

Durvalumab with transarterial chemoembolisation for treating incurable locally advanced hepatocellular carcinoma TS ID 10757

Tislelizumab for untreated unresectable hepatocellular carcinoma TS ID 10683

Atezolizumab with bevacizumab for adjuvant treatment of resected or ablated hepatocellular carcinoma at high risk of recurrence TS ID 10650

Durvalumab (Imfinzi) +/- bevacizumab (Avastin) for hepatocellular carcinoma TS ID 10736

Liver cancers Products

Filter

Product type

Guidance programme

Status1 selected

New and updated

Showing 12 products

Status
1 selected